Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases

Inclusion criteria

• ✓. The patient has signed the Informed Consent Form
• ✓. Progressive fibrosing ILD confirmed by high-resolution computed tomography (HRCT) documented evidence of \>10% lung tissue affected at Screening:
• ✓. To assess this criterion (I), patient's pulmonary function test (PFT) results obtained within 12 months prior to screening must available. If data from multiple PFTs are available, the earliest results must be used for assessment.
• ✓. Patients' results of at least one chest HRCT investigation performed no earlier than 24 months before randomization must be available for review. If results of multiple HRCT examinations are available, patient eligibility must be based on the earliest results.
• ✓. stable course of the main disease not requiring a change in maintenance treatment.
• ✓. ILD duration of no more than 8 years from the onset of respiratory symptoms by the date screening begins.
• ✓. Elevated acute phase reactants at screening not related to other causes:
• ✓. FVC ≥ 45% and ≤ 80% predicted at screening.